NL-OMON46258已完成2 期
A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in HPV-induced genital lesions of immunocompromised and immunocompetent patients. - ICVT in HPVinduced genital lesions of immunocompromised/-competent patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •For enrollment of subjects the following criteria must be met:
- •1. Vulvar HSIL or AGW patients, >= 18 years of age, in general, stable good health (with the exception of the immunocompromised disorder) as per judgment of the investigator based upon the results of a medical history, physical examination, ECG, chemistry, hematology.
- •2. In case of the immunocompromised patient group(s): having an immunosuppressive disease or receiving immunosuppressive therapy for any reason including but not limited to; patients with auto-immune disease, HIV patients, transplantation patients
- •3. In case of genital warts: have at least 3 genital warts (only applicable for study part 1)
- •4. In case of vulvar HSIL: at least one lesion that can be accurately measured (using RECIST criteria) in at least one dimension with longest diameter >=20 mm OR in 2 perpendicular dimensions that when multiplied together give a surface area >=120 mm² (only applicable for study part 1)
- •5. If female of childbearing potential, have a negative urine pregnancy test at Screening and Day 0, and is willing to use effective contraception during the study and 3 months afterwards (i.e. oral, implanted, injectable, IUD, diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy)
- •6. Able to participate and willing to give written informed consent and to comply with the study restrictions
- •7. Ability to communicate well with the investigator in the Dutch language
- •8. Willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study
排除标准
- •Eligible subjects must meet none of the following exclusion criteria:
- •1. Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the immunosuppressing disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease
- •2. Have used or received any topical genital wart treatment, cryotherapy, electrocoagulation, surgery in the treatment area within 28 days prior to enrolment
- •3. Have used or received any topical vulvar HSIL treatment, laser therapy or surgery in the treatment area within 28 days prior to enrolment
- •4. Have any current relevant skin infections in the treatment area other than genital warts (inclusively, but not limited to atopic dermatitis, lichen sclerosis, lichen planus or psoriasis)
- •5. Have a known sensitivity to any of the investigational product ingredients, including digoxin and furosemide
- •6. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year
- •7. Loss or donation of blood over 500 mL within three months prior to screening.
研究者
相似试验
进行中（未招募）
1 期
Digoxin / Furosemide topical therapy for genital warts and VIN lesions of immunocompromised and immunocompetent patientsEUCTR2016-000870-39-NLCutanea Life Sciences48
进行中（未招募）
不适用
A study in volunteers with cutaneous warts to assess safety and efficacy of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide.Patients with at least two warts who are otherwise healthy subjectsMedDRA version: 17.1Level: LLTClassification code 10010115Term: Common wartsSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10035158Term: Plantar wartsSystem Organ Class: 100000004864EUCTR2014-003688-39-NLCutanea Life Sciences
已完成
2 期
A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cutaneous WartsCutaneous warts10014982NL-OMON41194Centre for Human Drug Research80
进行中（未招募）
1 期
A study to investigate the efficacy and safety of a new medicinal product against external genital wartsPatients with external genital wartsMedDRA version: 19.0Level: LLTClassification code 10018182Term: Genital wartsSystem Organ Class: 100000004864EUCTR2015-005553-13-NLCutanea Life Sciences
已完成
2 期
A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS.voortplantingsstelsel- en borstaandoeningenvoortplantingsstelselinfecties en -ontstekingen, mannelijkCondylomata acuminataExternal genital warts10016417NL-OMON43535Cutanea Life Sciences24